Mouse Casp1 activation kit by CRISPRa

CAT#: GA200533

Casp1 CRISPRa kit - CRISPR gene activation of mouse caspase 1



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Cited in 1 publication.

Product images

经常一起买 (1)
CASP1 Rabbit polyclonal Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol Casp1
Locus ID 12362
Kit Components

GA200533G1, Casp1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA200533G2, Casp1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA200533G3, Casp1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_009807
Synonyms ICE; Il1bc
Summary Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis (By similarity). Upon inflammasome activation, during DNA virus infection but not RNA virus challenge, controls antiviral immunity through the cleavage of CGAS, rendering it inactive (PubMed:28314590). In apoptotic cells, cleaves SPHK2 which is released from cells and remains enzymatically active extracellularly (By similarity).[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Citations (1)

Documents

Other Versions

Customer Reviews 
Loading...